论文部分内容阅读
目的探讨儿童及青少年 Graves 病~(131)Ⅰ治疗的随访结果。方法对161例8～17岁儿童及青少年 Graves 病患者(男43例,女118例)进行~(131)Ⅰ治疗。甲状腺按其质量1.85～3.70 MBq/g给药,全疗程剂量范围74～1221 MBq,首次给药剂量中位数为185 MBq。随访24～104个月,平均(62±22)个月。结果失访14例(8.70%),治愈98例(60.87%),好转9例(5.59%),甲状腺功能亢进症(简称甲亢)复发3例(1.86%),甲状腺功能减退症(简称甲减)37例(22.98%)。随访期内未见患者生长发育受影响,亦无致癌致畸。~(131)Ⅰ治疗对患者及其后代无影响,除甲亢复发和甲减外没有其他不良反应和并发症。结论 ~(131)I治疗儿童及青少年甲亢安全有效。
Objective To investigate the follow-up results of Graves’ disease ~ (131) Ⅰ treatment in children and adolescents. Methods A total of 161 children aged 8-17 years and adolescents with Graves disease (male 43, female 118) were treated with ~ (131) Ⅰ. The thyroid gland is administered according to the mass of 1.85-3.70 MBq / g, the whole course of treatment is 74-1221 MBq, and the median dose for the first administration is 185 MBq. Followed up for 24 to 104 months, with an average of (62 ± 22) months. Results There were 14 patients (8.70%) lost the cure, 98 cases (60.87%) were cured, 9 cases (5.59%) were cured, 3 cases (1.86%) had hyperthyroidism recurrence, hypothyroidism ) 37 cases (22.98%). No patient’s growth and development were affected during the follow-up period, nor was it carcinogenic or teratogenic. 131I treatment had no effect on the patients and their offspring. There was no other adverse reactions and complications besides the relapse of hyperthyroidism and hypothyroidism. Conclusion ~ (131) I is safe and effective in the treatment of hyperthyroidism in children and adolescents.